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Activities of the Environmental Protection
Agency Concerning Phthalate Esters
by Steven D. Newburg-Rinn*
EPA's activities concerning phthalate esters have been in four general areas, namely: (1)
their status as toxic pollutants under the Clean Water Act; (2) their status as "new
chemicals" under Section 5 ofTSCA; (3) the potential risk to human beings posed by DEHP;
and (4) finally, the need for testing phthalates with respect to their health and environmental
effects.
Clean Water Act
Pursuant to Section 304(a)(1) ofthe Clean Water
Act, EPA is required periodically to review and
publish criteria for ambient water quality. Under
the authority of this section of the Act and in
satisfaction ofthe Settlement Agreement in Natu-
ral Resources Defense Council, et al., v. Train, 8
E.R.C. 2120 (1976), modified, 12 E.R.C. 1833
(D.D.C. 1979), EPA is required to publish criteria
documents for 65 pollutants which Congress, in the
1977 amendment to the Act, designated as toxic
under Section 307(a)(1). Among the 65 designated
compounds were the phthalate esters. In Novem-
ber, 1980, EPA's Office of Water Regulations and
Standards made available an ambient water quality
criteria document for several of the phthalate
esters. These Section304(a)(1) criteria are notrules
and they have no regulatory impact. Rather, these
criteria present scientific data and guidance on the
environmental effects of pollutants which can be
useful to derive regulatory requirements.
Under the Clean Water Act, these regulatory
requirements may include the promulgation of
waterquality-basedeffluentlimitationsunderSection
302, water quality standards under Section 303, or
toxic pollutant effluent standards under Section
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307. States are encouraged to incorporate criteria
for toxic pollutants, based on this guidance, into
their water quality standards. To date EPA has
promulgated no standards for the phthalate esters.
TheWaterQualityCriteriaDocumentforPhthalate
Esters was prepared prior to the public release of
NCI/NTP's di(2-ethylhexyl) phthalate (DEHP) bio-
assay results and therefore did not take into
account the NCI/NTP finding that DEHP was a
carcinogeninbothratsandmiceundertheconditions
ofthe test (1). The Office ofWater Regulations and
Standards is now in the process of updating the
criteria document to reflect these recent results.
The Office ofWaterRegulations and Standards is
also now considering a petition from Monsanto to
remove butyl benzyl phthalate (BBP) from the
priority pollutants list. No decision has yet been
made on this petition.
Premanufacture Review Notices
Under Section 5
of the Toxic Substances
Control Act (TSCA)
OnDecember 13, 1979, the EPAwasgivennotice
under Section 5 of TSCA of an intent to manufac-
ture (PMNs) six new chemicals, described as short-
chain polymers of phthalic acid and various mixed
alcohols and dihydric alcohols. What I am able to
say about these PMNs is somewhat limited by138
confidentiality claims. Nevertheless, thebasicissues
are not confidential business information and I will
briefly outline the facts. No health or environmen-
tal effects data were submitted by the manufac-
turer with its notice of intent to manufacture.
However, the similarity ofthe PMN substances to
alkyl phthalates allowed the Agency to use data on
existing alkyl phthalates to guide its preliminary
assessment of the PMN substances, Also during
the review period for the PMN substances the
Agency received preliminary reports concerning
the results ofthe NCI/NTP DEHP bioassay (1). In
view of the evidence of adverse health and envi-
ronmental effects ofcertain existingalkylphthalates
and the structural similarities of the PMN sub-
stances to those compounds, the Administrator
issued an order under Section 5(e) ofTSCA prohib-
iting the manufacture of these substances pending
the submission of data by the manufacturer to
clarify and define theirpotential hazards. Instead of
going forward with the process necessary to either
challenge orcomply with the Section 5(e) order, the
manufacturer chose instead to withdraw its request
to manufacture these six substances.
DEHP Assessment Activities
Having received the preliminary indication from
the NCI/NTP bioassay that DEHP was carcino-
genic in rats and mice, the Agency also began a
review of the potential cancer risk to humans that
DEHP might pose. Questions concerning DEHP's
carcinogenic potential are complex, as I am sure
that the agenda ofthis conference makes clear. The
Office ofToxic Substances has developed a prelimi-
nary risk assessment of DEHP which will be
presented elsewhere in this program (2). I do want
to note, however, that at this time questions
concerningthispreliminary evaluation ofthe poten-
tialrisk to humans posed by exposure to DEHP are
underreview atthe highest levels ofEPA. Because
no Agency-wide decision on DEHP's risk has yet
been made, I want to emphasize the preliminary
nature of this risk assessment of DEHP, and
caution you against interpreting these views as
EPA's position as an Agency on DEHP's risk to
humans.
Phthalate Testing Needs
The InteragencyTestingCommittee (ITC), estab-
lished under Section4(e) ofTSCA, recommended in
its First Report that the alkyl phthalates be tested
with respect to their environmental effects (3).
They noted the somewhat ubiquitous nature of
environmental phthalate exposure. In its Seventh
Report (submitted to the Agency after the prelimi-
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nary DEHP bioassay results were available), the
ITC addedbutylbenzylphthalate and butylglycolyl
butyl phthalate to the priority testing list under
TSCA, this time recommending both health and
environmental effects testing (4).
Talks between industry and EPA concerning
phthalate testing needs began in August of 1979
with a detailed submission from Monsanto on their
environmental testing program for the alkyl phtha-
lates (5). Monsanto already had an environmental
testing program in progress and they were inter-
ested in and willing to undertake additional volun-
tary testing for environmental effects.
Although the Agency was in the process of
evaluating health effects data on alkyl phthalates,
health effects were generally not perceived at that
time as a strongconcern forthat class ofcompounds
by either the Agency or industry. As these discus-
sions continued it became apparent that a joint
effort by the phthalate manufacturers would be
appropriate to broaden the scope of the testing
proposals. Monsanto agreed to meet with other
phthalate manufacturers through the Chemical Man-
ufacturers Association (CMA) to explore the possi-
bility ofajoint testing program. Their efforts were
quite successful and a meeting was set up between
EPA and industry which included representatives
from the CMA and five companies manufacturing
phthalates. This meeting marked the beginning of
CMA's key role in industry and EPA testing
discussions, which initially were focused on en-
vironmental and exposure concerns.
In early 1980, the Agency became aware of the
results of the NCI/NTP bioassay (1) on DEHP,
showingit to be acarcinogen in rats and mice under
the conditions of the test, and (2) on butyl benzyl
phthalate, where the results were equivocal under
the test conditions (6). The DEHP results height-
ened the concerns ofthe Office ofToxic Substances,
as well as those of the phthalate manufacturers,
over the possible human health risks of the alkyl
phthalates. A program for testing for both health
and environmental effects was therefore developed
by the manufacturers and users and coordinated by
the CMA (forming the Phthalate Esters Program
Panel). A summary presentation of this program
was made to the Agency in November of 1980,
followed by more detailed discussions. From the
start, the CMA program was reasonably compre-
hensive in the environmental area. However, the
health effects testing proposed at that time was
limited to a small group ofcompounds with a focus
on elucidating the mechanism of action for DEHP
regardingitsoncogenicity. Furthermeetings, then,
to expand the health effects testing and also to add
some additionaltestingtothe environmental effects
programwere held, beginningin Decemberof1980,
and continuing up until the present.EPA ACTION ON PHTHALATE ESTERS 139
As a final result of all of these meetings, the
Agency and the CMA appear to be close to an
agreement on an industry-sponsored program of
testing which matches the major testing needs of
the Agency. Industry's voluntary program will
answer environmental effects questions relating to
toxicity to aquatic organisms, environmental fate
and transport and biodegradation of all fourteen
identified high production alkyl phthalates and
benzyl butyl phthalate. These compounds are pro-
duced in quantities near or greater than ten million
pounds per year. As will be explained elsewhere in
this program (7), the CMA proposal also includes a
screening program to examine the health effects
issues ofoncogenicity and mutagenicity for a some-
what smaller group of nine alkyl phthalates and
benzyl butyl phthalate (8). Selection of these com-
pounds was based on both production and chemical
structure considerations. Positive results for a
given chemical will result in additional, long-term
testing and screening of more chemicals in that
particular chemical's subcategory. It is proposed by
CMA that cooperation of the Agency and industry
extend through the testing program. When CMA's
detailed proposal is received by the Agency in the
near future, we will be examining it very carefully
to determine whether these voluntary efforts will
make necessary a regulation requiring the health
and environmental effects testing of the phthalate
esters.
A few notes about the CMA health testing
program are in order. It may appear on first
impression that EPA's needs fortesting differ from
CMA's. I do not think this is so. Both industry and
EPA need to know more about phthalate toxicity,
and government has no investment in phthalates
being found to be either human health or environ-
mental risks. While the CMA program is clearly
experimental, it clearly could establish the toxicity
of phthalates in addition to DEHP. I believe that
our knowledge of phthalate toxicity will apprecia-
bly advance if CMA goes forward with this pro-
gram. (Since this conference, the EPA has accept-
ed, as of October 30, 1981, a CMA proposal to do
health and environmental effects testing of the
alkyl phthalates on a voluntary basis.)
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